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Abstract
Background: The epidemiology of invasive meningococcal disease (IMD) in Québec, Canada, has been dominated
in the past decade by a clone of serogroup B (MenB) Neisseria meningitidis defined by multi-locus sequence typing
(MLST) as sequence type (ST)-269. With the licensure of a new MenB vaccine Bexsero (4CMenB) in Canada, this
study characterized invasive N. meningitidis recovered in Québec from 2009 to 2013, with an objective to examine
the diversity of the 4CMenB vaccine antigens. Isolates were serogrouped by antisera and genogrouped by PCR, and
further typed by whole cell ELISA for serotype and serosubtype antigens. Clonal analysis was done by MLST. Isolates
were genotyped by analysis of their 4CMenB vaccine antigen genes of PorA, factor H binding protein (fHbp),
Neisserial Heparin Binding Antigen (NHBA), and Neisseria Adhesin A (NadA).
Results: Of the 263 IMD isolates analysed, 229, 16, 10, 7, and 1 belonged to MenB, MenY, MenW, MenC, and MenX,
respectively. Of the 229 MenB, 159 (69.4 %) were typed as ST-269 clonal complex (CC); and they possessed a
restricted number of three fHbp and five nhba gene alleles. Nine N. meningitidis isolates (eight MenB and one
MenY) were found to possess at least one gene that encoded for an antigen that matched exactly with protein
variants in the 4CMenB vaccine. Two MenB expressed PorA antigen P1.4 and possessed the nhba gene for peptide
2; four other MenB were predicted to have NHBA peptide 2; another two MenB were predicted to encode fHbp
peptide 1.1; and a single MenY was found to have nadA gene for NadA peptide 8. In addition, another 172 isolates
were found to possess genes for variant 1 fHbp peptides other than peptide 1.1 or NadA variant 1-2/3 peptides
other than peptide 8; and therefore, may potentially be covered by 4CMenB.
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Conclusion: The most prevalent clone of N. meningitidis in Quebec was ST-269 CC; and 96 % of the isolates in this
CC were predicted to be covered by 4CMenB vaccine. Extensive genetic diversity was found in the other IMD
isolates in Québec which might suggest a lower coverage by the vaccine when compared to the ST-269 MenB.
Keywords: Invasive Neisseria meningitidis, 4CMenB protein vaccine targets
Background
Neisseria meningitidis is a Gram-negative diplococcus
which infects only humans. On average 10 % of healthy
individuals may carry this bacterium in their nasophar-
ynx, and due to reasons not completely understood, the
bacterium sometimes gains access into the blood stream
and causes systemic diseases such as meningitis, septi-
cemia, and occasionally localised infections in the joint,
and heart [1]. Six of the 12 known serogroups (A, B, C,
W, X, and Y) of meningococci are responsible for most
of the invasive diseases which occur worldwide [2, 3].
Although all 6 serogroups may cause outbreaks, sero-
groups A, B, C, and W have caused epidemics that may
spread globally [4]. Case fatality rates associated with the
different serogroups and in particular clonal groups may
also vary [5, 6].
Besides the capsule, typing of N. meningitidis is usually
based on surface antigens or their genes, such as the
PorB and PorA (corresponding to serotype and serosub-
type antigens, respectively), as well as non-cell surface
components such as housekeeping enzymes or their
genes using the method of multilocus enzyme elec-
trophoresis or multilocus sequence typing (MLST), re-
spectively [7]. The surface antigens and their genes are
under constant selective pressure and therefore, result-
ing in greater diversity which made them suitable only
for short term or localised epidemiological tracking. In
contrast, housekeeping enzymes and their genes are neu-
tral (not under selection) and are therefore, ideal targets
for long term and global epidemiology [4]. In MLST, iso-
lates with unique allelic profiles are assigned to sequence
types (STs) and related STs are grouped together into
clonal complexes (CCs). Most IMD, especially those oc-
curring in clusters or epidemics are caused by strains
recognised as hypervirulent clones [4]. Other additional
targets may include the iron-regulated outer membrane
protein FetA [8], as well as other potential non-capsule
protein-based vaccine components (see below).
The capsules of meningococci are well known viru-
lence factor by offering the pathogen resistance to innate
immunity including activation of the alternative pathway
of complement. Therefore, vaccines based on capsules of
serogroups A, C, W, and Y (MenA, C, W, and Y) have
been successfully used to control these serogroups of
meningococci [9]. However, the capsule of serogroup B
meningococci (MenB) is non-immunogenic due to its
cross-reactivity to host tissue and therefore, deve-
lopment of a MenB vaccine based on its capsule is not
feasible [10]. Genome sequencing of N. meningitidis [11]
has opened a new approach, called reverse vaccinology,
to vaccine development [12]. Two new MenB vaccines
have been licensed in some countries. Protein-based
meningococcal vaccines developed against MenB may
have the potential to protect also against many clones
belonging to any serogroups, including MenC, MenY,
and MenW [13] or even non-capsular clones. The
4CMenB vaccine or Bexsero® (Novartis) [14] is licensed
for use in Europe, Canada, the United States, and Australia,
while the recombinant bi-valent vaccine Trumenba® based
on factor H binding protein (fHbp), also known as lipo-
protein LP2086 [15], is licensed for use in the United
States. The Bexsero® vaccine is made up of three major
components, fHbp, subfamily B or variant 1, peptide 1;
Neisserial Heparin Binding Antigen (NHBA) peptide 2;
Neisseria Adhesin A (NadA) peptide 8, combined with the
outer membrane vesicle (OMV) vaccine prepared from
the New Zealand MenB strain NZ98/254 which has been
used for control of the MenB epidemic in New Zealand
caused by the MenB strain of B:4:P1.4 (Lineage 3 or
ST-41/44 CC) [16]. Meningococcal fHbp is divided into 2
subfamilies, A and B which correspond to variant 2/3 and
1, respectively [17, 18]. Proteins within a subfamily share a
relatively high degree of similarity and therefore, cross-
protection between peptides within a subfamily is feasible
while peptides between subfamilies are more divergent
and do not provide cross-protection [18]. Variants of
NHBA have also been shown in animal studies to offer
cross-protection [19]. NadA is made up of at least 4 vari-
ants, 1, 2/3, 4/5, and 6; with proteins within variants 1,
and 2/3 shown to provide cross-protection [20]. The pro-
tection afforded by OMV vaccine is PorA or serosubtype-
specific and the major immunological epitope resides
on the PorA VR2 region. Thus OMV vaccine made
from MenB strain NZ98/254 offers only protection
against meningococcal strains expressing the PorA anti-
gen P1.4 [16].
The epidemiology of invasive meningococcal disease
in Québec, Canada, has been dominated by the ST-269
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clone of MenB in the last decade associated with out-
breaks or clusters of cases in certain regions of the prov-
ince [21]. The aim of the current study is to document
the trend since our last report as well as to expand on
our previous studies to include an analysis of the genetic
diversity of the newer MenB vaccine antigens, i.e. fHbp,
NHBA, NadA, and PorA. This study will provide good
baseline data before the newer MenB vaccines are intro-
duced in the population.
Methods
Isolates of N. meningitidis
Individual IMD case isolates (n = 263), defined by their
isolation from normally sterile body sites of individual
patients were included in this study. These isolates con-
stituted all the IMD isolates received at the National
Microbiology Laboratory (NML) of the Public Health
Agency of Canada between the period of 1 January 2009
and 31 December 2013.
Identification and typing of N meningitidis
Isolates of N. meningitidis were identified at the local
hospitals and their identity was confirmed and they were
serogrouped at the Laboratoire de santé publique du
Québec using rabbit anti-meningococcal antisera pro-
duced by the NML. Identification of serotype and serosub-
type was done by a monoclonal antibody kit containing
antibodies to serotypes 1, 2a, 2b, 4, 14, and 15; and sero-
subtypes P1.1, P1.2, P1.4, P1.5, P1.6, P1.7, P1.9, P1.10,
P1.12, P1.13, P1.14, P1.15, and P1.16 (Rijksinstitut voor
Volksgezondheid en Milieu, National Institute of Public
Health, Bethoven, The Netherlands) using indirect whole
cell ELISA [22]. Mouse monoclonal antibodies to serotype
2c, 17, 19, and serosubtype P1.19 were kind gifts from
Dr. Wendell Zollinger of the Walter Reed Army Institute
of Research (Maryland, U.S.A.). Clonal analysis was done
by MLST [23] and ST/CC were assigned using tools avail-
able in the Neisseria MLST website (http://pubmlst.org/
neisseria/). PorA genotype was determined by PCR ampli-
fication of the variable region gene fragments followed by
standard DNA sequencing technique using published
methods [24, 25]. The nomenclature given in the N.
meningitidis PorA variable region database (http://pub-
mlst.org/neisseria/PorA/) and by de Filippis et al. [26] was
followed. The fHbp, nhba, and nadA gene sequences were
determined by PCR amplification and standard sequen-
cing reactions following the protocols described by Luci-
darme et al. [27]; and their peptide types were determined
by the online tools available from the Neisseria.org website
(http://pubmlst.org/neisseria). The nomenclature scheme
for fHbp peptide according to Novartis was used: e.g.
variant 1, peptide 1 was described as 1.1, etc.
Phylogenetic trees were constructed based on the
predicted amino acid sequences of fHbp and NHBA
peptides using software provided in the DNASTAR
Lasergene 12.1 (Madison, Wisconsin, U.S.A.).
Results
Serogroup distribution per year
During the period 2009-2013, 352 IMD cases were re-
ported to Public Health authorities in Québec. Our
study included 263 individual case isolates obtained
from culture-confirmed IMD patients which constituted
75 % of all IMD reported in Québec. Overall, there were
229 (87 %) MenB, 16 (6 %) MenY, 10 (4 %) MenW,
7 (3 %) MenC, and 1 isolate of MenX (Table 1). This
study did not include the culture-negative and PCR
diagnosed IMD cases, and this might be the major rea-
son for the smaller number of case isolates included in
this study compared to the total number of cases re-
ported in the province.
Clonal analysis of MenB
Among the 229 individual MenB case isolates, 220 or
96 % were grouped by MLST into 11 CCs, while 9
isolates did not belong to any known CC according to
the current MLST typing scheme (http://pubmlst.org/
neisseria/; accessed April 30, 2015). The most commonly
occurring CCs were ST-269 CC (n = 159 or 69.4 %),
followed by ST-41/44 CC (n = 43 or 18.8 %), ST-32 CC
(n = 5 or 2.2 %), ST-35 CC (n = 4 or 1.8 %), and ST-461
CC and ST-1157 CC (each with 2 isolates or 0.9 %).
There were also 5 other CCs (ST-37, ST-60, ST-103,
ST-213, and ST-254 CCs) each with only a single isolate
(see Additional file 1: Table S1).
Despite being the most frequently occurring CC with
159 isolates, 91 % (n = 145) of the isolates in the ST-269
CC belonged to a single ST (ST-269). There were 9
other STs with 7 of them (ST-565, ST-1986, ST-5494,
ST-8767, ST-8772, ST-8924, and ST-8880) being single
locus variants (SLVs) of ST-269 while ST-13 and ST-2738
were double, and triple locus variants, respectively. Most
(n = 150 or 94 %) expressed the serotype antigen 17, with
8 isolates being non-serotypeable (NT), and 1 isolate of
serotype 14,19. One hundred and twenty two isolates
Table 1 Distribution of Neisseria meningitidis serogroups among
culture-positive invasive meningococcal disease cases in
Québec, Canada, 2009-2013
Number (%) of cases by serogroups Total #
of casesYears B C Y W135 X
2009 49 (90.7) 1 (1.9) 1 (1.9) 3 (5.5) 0 (0.0) 54
2010 42 (87.5) 2 (4.2) 3 (6.2) 1 (2.1) 0 (0.0) 48
2011 50 (83.3) 1 (1.7) 5 (8.3) 3 (5.0) 1 (1.7) 60
2012 41 (82.0) 3 (6.0) 5 (10.0) 1 (2.0) 0 (0.0) 50
2013 47 (92.2) 0 (0.0) 2 (3.9) 2 (3.9) 0 (0.0) 51
All years 229 (87.0) 7 (2.7) 16 (6.1) 10 (3.8) 1 (0.4) 263
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(77 %) expressed the serosubtype antigen P1.19 and 25
isolates (16 %) expressed the serosubtype antigen P1.9.
There were 6 isolates that were non-serosubtypeable
(P1.-), and 1 isolate each of serosubtypes P1.6; P1.7; P1.12;
P1.16; P1.5,2; and P1.15,29.
In contrast to the ST-269 CC, the 43 MenB case iso-
lates that belonged to the ST-41/44 CC were grouped
into 23 different STs (Additional file 1: Table S1). Al-
though 1 ST (ST-571) was common (responsible for 16
isolates or 37 % of the ST-41/44 CC), 19 other STs were
represented by a single isolate only, and another 3 STs
with multiple isolates (ST-944, n = 3; ST-282, n = 3; and
ST-41, n = 2). The diversity of the ST-41/44 CC isolates
was also reflected in their serotype and serosubtype anti-
gens. Altogether, there were 7 different combinations of
serotype antigens, including seventeen isolates of sero-
type 19; fourteen of serotype 4; four of serotype 15,19;
three of serotype 17; two of serotype 1,19; and one each
of serotypes 15, and 14,19. There was only one isolate
that was non-serotypeable (NT). There were 8 different
combinations of serosubtype antigens, including twenty
of P1.9; five of P1.6; three of P1.13; two each of P1.4;
P1.5; P1.12; and one each of P1.14; and P1.5, 2. Seven
isolates were non-serosubtypeable (P1.-). The antigenic
formula of the ST-571 isolates appeared to be generally
uniform with thirteen isolates typed as B:19:P1.9; and
one isolate each of B:1,19:P1.9; B:15,19:P1.9; and
B:15,19:P1.-.
The other MenB case isolates (n = 27), whether be-
longing to a known CC or that did not belong to any
known CC, were in general presenting diverse STs, sero-
type or serosubtype antigens. No one ST, nor serotype/
serosubtype was found in large numbers.
Clonal analysis of non-group B meningococci
All 7 MenC isolates belonged to ST-11 (ST-11 CC) and
expressed the serotype antigen 2a. Three different sero-
subtype antigen combinations were detected including
four isolates of P1.5; two isolates of P1.7,1; and one iso-
late of P1.2.
The four different STs found among the 10 MenW
isolates all belonged to the ST-22 CC. Besides the single
isolate of ST-22, there were 7 isolates of ST-184, and 1
isolate each of ST-1617 and ST-2625; with the latter 3
STs being SLVs of ST-22. All ten MenW were NT; five
were positive for P1.6; one was positive for P1.14; and
four were P1.-.
Twelve of the 16 MenY were grouped into 4 CCs, with
ST-23 CC being the most common, made up of 6 iso-
lates, followed by ST-167 CC with 4 isolates, and 1 iso-
late each of ST-174 CC and ST-22 CC. Four MenY
isolates were not classified into any known CC. Half of
the MenY isolates were NT; and the remaining 8 isolates
presented 4 different combinations of serotype antigens
including four with serotype 14,19; two with serotype 2c;
and one each of serotype 19, and 15,19. Four different
combinations of serosubtype antigens were found among
the MenY isolates, including six isolates with P1.5; five
with P1.5,2; and one each of P1.6 and P1.9. Three MenY
were P1.-. Nine different combinations of serotype:sero-
subtype combinations were found among the 16 MenY
isolates (data provided in Supplementary Table S1, see
Additional file 1).
Characteristics of non-carbohydrate protein-based
vaccine targets in MenB
Similar to the clonal data of MenB isolates, a limited
number of fHbp and NHBA peptide types were predicted
among isolates in the ST-269 CC (Additional file 2:
Table S2). There were only three fHbp peptide types iden-
tified with 152 isolates predicted to have fHbp peptide
1.15; five for peptide 2.19 and one for peptide 1.249. In
one isolate, no peptide was predicted based on its fHbp
gene sequence identified as allele 755 which contained a
frame-shift mutation. The five NHBA peptide types pre-
dicted to be produced by isolates of the ST-269 CC in-
cluded peptide 21 (149 isolates), peptide 770 which
differed from peptide 21 by only 1 amino acid (4 isolates),
peptide 6 (3 isolates), peptide 768 (2 isolates), and peptide
122 (1 isolate).
In contrast to isolates in the ST-269 CC; isolates of
ST-41/44 CC were also more diverse in their fHbp and
nhba gene sequences (Additional file 2: Table S2). Ten
fHbp gene alleles together with five nhba gene alleles
were found among isolates in the ST-41/44 CC. They
predicted fHbp peptides 1.4 (n = 4), 1.14 (n = 1), 2.19
(n = 26), 2.23 (n = 2), 2.24 (n = 2), 3.30 (n = 1), 1.100 (n = 1),
1.410 (n = 4), 2.632 (n = 1), and 1.687 (n = 1); and NHBA
peptides 2 (n = 6),10 (n = 4), 29 (n = 4), 47 (n = 3), 112
(n = 25), and 286 (n = 1).
The remaining MenB isolates were made up of many
different STs belonging to 9 CCs as well as some that
were not assigned to any known CC. Because the num-
ber of isolates in each CC or ST were very small, they
would not be described individually but were grouped
together for an overview of MenB strains. Of the 229
MenB IMD isolates in Québec, 25 fHbp peptide types
were identified based on their fHbp gene sequences,
including 12 peptide types with 175 isolates (76.4 %)
belonging to variant 1 or subfamily B; and 13 peptide
types with 52 isolates (22.7 %) belonging to subfamily A
(10 peptides with 47 isolates belonged to variant 2; and 3
peptides with 5 isolates belonged to variant 3) (Table 2).
In addition, there was 1 isolate with a fHbp gene allele 755
that did not suggest a peptide would be produced and
another isolate (ST-6977) whose fHbp gene sequence sug-
gested a genetic recombination, similar to that described
for strain M99 241177 (GenBank JF916571) [28]. Based
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on their nhba gene sequences, 21 NHBA peptide types
were expected to be present in the 229 MenB isolates in
Québec. The most common NHBA peptide was peptide
21 with 154 isolates and another 4 isolates predicted to
synthesise peptide 770, which was related to NHBA peptide
21 but with only 1 amino acid difference. Other common
NHBA peptide types included peptide 112 (25 isolates),
peptide 2 (6 isolates), and peptides 6, 10, 47, and 122, each
with four isolates. The remaining NHBA peptide types
were made up of either 1 or 2 isolates each (Table 3).
The nadA gene could not be detected in MenB strains
belonging to ST-269 and ST-41/44 CCs. In the other
MenB strains, the nadA gene could only be found in
Table 2 Factor H binding protein (fHbp) peptide types in
invasive Neisseria meningitidis from Québec, Canada, 2009-2013
Novartis variant 1 Peptides # of isolates (serogroup)
(Pfizer subfamily B) 1.1 2 (B, two ST-32 cc)
1.4 5 (B, four ST-41/44 cc, one ST-35 cc)
1.12 2 (B, one UAa; C, one ST-11 cc)
1.13 5 (B, one ST-60 cc, one ST-254 cc,
two ST-1157 cc, one UA)
1.14 1 (B, ST-41/44 cc)
1.15 152 (B, 152 ST-269 cc)
1.100 1 (B, ST-41/44 cc)
1.110 1 (B, UA)
1.129 1 (C, ST-11 cc)
1.144 1 (B, ST-32 cc)
1.218 1 (C, ST-11 cc)
1.249 1 (B, ST-269 cc)
1.278 1 (Y, ST-167 cc)
1.410 4 (B, four ST-41/44 cc)
1.687 1 (B, ST-41/44 cc)
Novartis variant 2 2.16 15 (3B, three ST-35 cc; 1C, ST-11 cc;
2Y, one ST-22 cc; one UA; 9W, nine
ST-22 cc)
(Pfizer subfamily A)
2.19 32 (31B, five ST-269 cc; 26 ST-41/
44 cc;
1×, one ST-32 cc)
2.21 1 (Y, ST-174 cc)
2.22 1 (B, ST-32 cc)
2.23 6 (3B, two ST-41/44 CC; one ST-37
cc; 3Y, one ST-167 cc; two UA)
2.24 5 (4B, two ST-41/44 cc, two UA;
1Y, ST-167 cc)
2.25 9 (1B, ST-103 cc; 7Y, six ST-23 cc;
one ST-167 cc; 1 W, ST-22 cc)
2.102 2 (1B, ST-213 cc; 1C, ST-11 cc)
2.106 1 (B, UA)
2.527 1 (B, UA)
2.629 1 (Y, UA)
2.632 1 (B, ST-41/44 cc)
Novartis variant 3 3.30 2 (B, ST-41/44 cc, ST-32 cc)
(Pfizer subfamily A) 3.47 2 (B, two ST-461 cc)
3.555 1 (B, UA)
No peptide allele 669 2 (C, two ST-11 cc)




aUA = not assigned to any known clonal complex by pubmlst.org/neisseria
Table 3 Neisserial Heparin Binding Antigen (NHBA) peptide




# of isolates (serogroup)
2 6 (B, six ST-41/44 cc)
3 2 (B, two ST-32 cc)
5 2 (B, two ST-32 cc)
6 6 (4B, three ST-269 cc; one UAa; 2Y; two ST-23 cc)
7 2 (Y, two ST-23 cc)
8 2 (Y, two ST-23 cc)
9 6 (Y, three ST-167 cc; three UAa)
10 4 (B, four ST-41/44 cc)
12 1 (B, ST-37 cc)
20 21 (2B, one ST-32 cc; one ST-254 cc;
7C, seven ST-11 cc; 10W; ten ST-22 cc; 2Y, one ST-22 cc,
one UA)
21 154 (B, 149 ST-269 cc, three ST-35 cc, two UA)
24 2 (B, one ST-60 cc, one ST-103 cc)
29 6 (B, four ST-41/44 cc, one ST-213 cc, one UA)
47 4 (B, three ST-41/44 cc, one UA)
112 25 (B, 25 ST-41/44 cc)
114 2 (B, two ST-1157 cc)
122 4 (B, one ST-269 cc, three UA)
197 1 (B, ST-461 cc)
286 1 (B, ST-41/44 cc)
287 1 (B, UA)
680 1 (Y, ST-174 cc)
766 1 (B, ST-461 cc)
767 1 (X, ST-32 cc)
768 2 (B, two ST-269 cc)
769 1 (Y, ST-167 cc)
770 4 (B, four ST-269 cc)
771 1 (B, ST-35 cc)
aUA = not assigned to any known clonal complex by pubmlst.org/neisseria
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isolates belonging to the ST-32 CC (n = 5); ST-1157 CC
(n = 2); ST-213 CC (n = 1), and ST-336 (n = 1). However,
the nadA genes in isolates of ST-1157 CC (allele 20) and
ST-213 CC (allele 34) did not predict to produce any
peptide due to frame-shift mutations. In the single iso-
late of ST-336, the nadA gene was found to predict
NadA-2/3 peptide 3. Four of the 5 ST-32 CC isolates
had the nadA gene which predicted NadA-1 peptide 1;
while the nadA gene in the fifth isolate was predicted to
encode NadA-1 peptide 85.
Among the 229 MenB case isolates, only two ex-
pressed the serosubtype antigen P1.4; with the PorA
genotype of P1.7-2,4,37. Both isolates belonged to the
ST-41/44 CC (one being of ST-41 and the other was
ST-154).
Characteristics of non-carbohydrate protein-based
vaccine targets in non-serogroup B meningococci
In two of the seven MenC isolates, their fHbp gene allele
669 contained a frame-shift mutation that led to a prema-
ture stop codon and therefore, no fHbp peptide would be
expected in them. The other five isolates each have a dif-
ferent fHbp gene allele predicting the following fHbp pep-
tides (1.12, 2.16, 2.102, 1.129, and 1.218); three of which
belonged to variant 1 and two to variant 2. The nadA
genes (allele 29) in four MenC isolates were disrupted by
presence of an IS1301 element, and therefore, no peptide
were expected in them. In one MenC isolate, its nadA
gene predicted a NadA-2/3 peptide 2; and in two MenC
isolates, their nadA gene predicted a NadA-2/3 peptide 3.
All seven MenC isolates were found to have nhba genes
that predicted a NHBA peptide 20.
Of the 16 MenY isolates, seven fHbp peptide types
were predicted based on their fHbp gene sequences.
Other than the one isolate that was predicted to produce
a variant 1 fHbp peptide 1.278, the remaining 15 MenY
isolates were predicted to encode variant 2 fHbp pep-
tides 2.16, 2.21, 2.23, 2.24, 2.25, and 2.629; with peptide
2.25 being the most common peptide found in seven iso-
lates. Seven NHBA peptide types (6, 7, 8, 9, 20, 680, and
769) were identified based on their nhba gene sequences.
Peptide 680 was related to peptide 6 but with 1 amino
acid difference. Only the single ST-1466 (ST-174 CC)
MenY was found to have a nadA gene allele 80, which
predicted a NadA-2/3 peptide 8. The nadA gene was not
detected in all the other MenY isolates.
All ten MenW isolates were found to have fHbp genes
that encoded for variant 2 peptides, with nine of them
predicted to encode for peptide 2.16, and only one iso-
late was predicted to produce a fHbp peptide 2.25. All
ten MenW were found to have nhba gene allele en-
coding for NHBA peptide 20. None of the MenW was
found to harbor the nadA gene and therefore, no NadA
protein was expected to be present in these MenW
isolates.
The single MenX was found to have fHbp and nhba
genes to encode for fHbp peptide 2.19 (variant 2), and
NHBA peptide 767. No nadA gene was detected in the
MenX isolate.
Predicted coverage by the 4CMenB vaccine based on
vaccine target gene sequence analysis
There were altogether 30 fHbp peptide types identified
among the invasive N. meningitidis strains found in
Québec. Their frequencies of occurrence in different ser-
ogroups are described in Table 2. In addition, there were
3 isolates with fHbp gene mutations that would prevent
synthesis of a mature fHbp peptide. In another isolate,
there was a recombination resulting in an interruption
of its fHbp gene by a foreign unrelated gene (GenBank
JF916571) [28]. There were 27 different NHBA peptide
types and their distribution according to serogroup is
described in Table 3.
For MenB isolates, none was found to have more than
two vaccine antigens that matched exactly with the
4CMenB components and only two isolates were found to
have PorA P1.4 and NHBA peptide 2 that matched exactly
with the respective components found in the vaccine. An-
other six MenB isolates were found to have one antigen,
either fHbp peptide 1.1 (two isolates) or NHBA peptide 2
(four isolates), that matched exactly with the correspond-
ing component found in the 4CMenB vaccine (Table 4).
Assuming all isolates with fHbp variant 1 and NadA vari-
ants 1 and 2/3 peptides would be covered by the vaccine,
two MenB isolates might be regarded to be covered by
three components of the vaccine by virtue of their PorA
P1.4, fHbp peptide 1.4, and NHBA peptide 2 antigens; and
five MenB isolates might be regarded to be covered by
two components of the vaccine by virtue of their variant
1 fHbp peptides and NHBA peptide 2 (four isolates), and
variant 1 fHbp peptide and NadA peptide 85 (one isolate).
Another 166 MenB isolates were considered to be covered
by one component of the vaccine: variant 1 fHbp (163 iso-
lates) or NadA variants 1, 2/3 peptides (3 isolates).
For the non-serogroup B IMD strains in Québec, none
was found to have fHbp and nhba genes encoding
for fHbp peptide 1.1 and NHBA peptide 2. However 1
MenY isolate (ST-1466) was found to possess a nadA
gene for NadA peptide 8 found in the 4CMenB vaccine.
Another 4 isolates (3 MenC and 1 MenY) were found to
have fHbp genes that predicted variant 1 fHbp peptides.
Also 3 MenC were found to have nadA genes encoding
for NadA-2/3 peptides, likely to have enough similarity
with the NadA peptide component in the 4CMenB to be
regarded as covered by the vaccine.
Regardless of serogroup, a total of 9 isolates could be
regarded to be covered by the 4CMenB vaccine by
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possession of at least 1 antigen showing an exact match
to the vaccine components; and an additional 172 iso-
lates might be covered by virtue of possession of at least
1 antigen showing a partial match with the vaccine com-
ponents, e.g. fHbp variant 1 peptides.
The diversity of the fHbp and NHBA peptides found
in the invasive N. meningitidis strains in Québec are
presented in Figs. 1 and 2, respectively. With respect to
fHbp peptides, even among the variant 1 peptides, con-
siderable amino acid diversity was found among IMD
isolates in Québec (Fig. 1; bottom half of the figure). In
addition, it was evident that peptides of the variants 2
and 3 were more distantly related to peptides that be-
long to variant 1. Similarly, NHBA peptides found in the
Table 4 Invasive Neisseria meningitidis from Québec, Canada in 2009-2013: predicted vaccine coverage based on at least one antigen
showing an exact match to the 4CMenB vaccine components or with Novartis variant 1 factor H binding protein (fHbp)/Neisseria
adhesin A (NadA) peptides belonging to variants 1 to 3
Predicted coverage based on exact match to 4CMenB componentsa
CC ST Serogroup # of isolates fHbpb NHBA NadA-2/3c PorA
ST-41/44 ST-41 B 1 Possibly, 4 Yes No Yes
ST-154 B 1 Possibly, 4 Yes No Yes
ST-41 B 1 Possibly, 4 Yes No No
ST-1194 B 1 Possibly, 4 Yes No No
ST-8052 B 1 Possibly, 14 Yes No No
ST-10619 B 1 Possibly, 100 Yes No No
ST-32 CC ST-32 B 2 Yes, 1 Unknown No No
ST-174 CC ST-1466 Y 1 No Unknown 8 No
Additional coverage based on strains predicted to express NadA-1,2/3 and/or Novartis variant 1 fHbp peptides
ST-269 CC ST-269 B 143 Possibly, 15 Unknown No No
ST-1986 B 4 Possibly, 15 Unknown No No
ST-5494 B 3 Possibly, 15 Unknown No No
ST-8767 B 1 Possibly, 15 Unknown No No
ST-8880 B 1 Possibly, 15 Unknown No No
ST-2738 B 1 Possibly, 249 Unknown No No
ST-32 CC ST-33 B 1 Possibly, 144 Unknown 85 No
ST-2726 B 2 No Unknown 1 No
ST-35 CC ST-278 B 1 Possibly, 4 Unknown No No
ST-1157 CC ST-1157 B 2 Possibly, 13 Unknown No No
ST-60 CC ST-10587 B 1 Possibly, 13 Unknown No No
ST-254 CC ST-10332 B 1 Possibly, 13 Unknown No No
Not assignedd ST-336 B 1 No Unknown 3 No
ST-7655 B 1 Possibly, 13 Unknown No No
ST-7704 B 1 Possibly, 110 Unknown No No
ST-9248 B 1 Possibly, 12 Unknown No No
ST-11 CC ST-11 C 2 No Unknown 3 No
ST-11 C 1 No Unknown 2 No
ST-11 C 1 Possibly, 12 Unknown No No
ST-11 C 1 Possibly, 129 Unknown No No
ST-11 C 1 Possibly, 218 Unknown No No
ST-167 CC ST-6171 Y 1 Possibly, 278 Unknown No No
a4CMenB vaccine components include: factor H binding protein (fHbp) peptide 1; Neisseria Heparin Binding Antigen (NHBA) peptide 2; Neisseria adhesion A (NadA)-2/3
peptide 8; and outer membrane protein porin A (PorA) P1.4
bNovartis variant 1 peptides were indicated by their peptide number possibly covered by the vaccine; whereas variants 2/3 peptides were labelled as No to
indicate no match or not covered by the 4CMenB vaccine
cNadA variant 1-3 peptides were indicated by their peptide number; whereas No was used to indicate absence of the nadA gene
dNot assigned to any known clonal complex according to the current Neisseria MLST website (http://pubmlst.org/neisseria/)
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Québec IMD isolates were also grouped into clusters,
with some clusters of peptides showing various degree
of diversity with the vaccine peptide 2 (Fig. 2).
Discussion
Factor H binding protein (fHbp) is one of Neisseria
meningitidis virulence factors and is found in two men-
ingococcal vaccines, Bexsero® and Trumenbal®. Cha-
racterization of fHbp from various N. meningitidis
strains have identified 2 subfamilies (A and B) or 3 vari-
ants (variants 1, 2, 3) of fHbp. Subfamily A fHbp is
equivalent to variants 2 and 3 while subfamily B fHbp is
equivalent to variant 1. Immunological cross-reactivity
and cross-protection between different fHbp within a
subfamily have been observed but this is not extended
to fHbp from different subfamilies [18]. Bexsero® also
known as 4CMenB, is made up of multi-components
with fHbp being only one of them. The fHbp present in
this vaccine is restricted to peptide 1.1 from subfamily B,
which presumably will cover strains expressing subfamily
B fHbp. Broader protective nature of Bexsero® is ex-
tended by its other components, including NHBA, NadA
and PorA P1.4. On the other hand, Trumenbal® is com-
posed of only fHbp but it is a bivalent fHbp vaccine with
2 peptides present representing both subfamily A and
subfamily B that allows it to cover strains expressing
either subfamily of fHbp. This study provided a com-
prehensive genetic analysis of this virulence factor found
in invasive N. meningitidis strains in the province of
Quebec, Canada over the five years period of 2009-2013,
just before the licensure of either of these vaccines.
This study was based on our previous reports of a
changing epidemiology of IMD in the province of
Quebec [21, 29, 30] but the focus was on characteristics
of invasive N. meningitidis strains and the genetic diver-
sity of vaccine antigens found in the newer MenB vac-
cines. Results of this study documented the continued
dominance of MenB as a cause of IMD in Québec, with
92 % of the IMD case isolates in 2013 belonging to this
serogroup (Table 1), and in particular the ST-269 CC.
Compared to the study that examined IMD case isolates
in Québec from 2003 to 2010 which consisted of 180
MenB isolates belonging to the ST-269 CC with 91.7 %
due to a strain typed as ST-269 [30], the present study
showed that the % of ST-269 isolates in the ST-269 CC
has not changed and remained as 91.2 % (145 of 159
isolates of MenB ST-269 CC). In the original report of
the emergence of the ST-269 clone, there were only 3
STs identified among the MenB isolates in this CC in
Québec [29]. Then the number of STs within this CC
expanded to involve 11 STs [30], with 8 STs newly iden-
tified when compared to the previous finding [29]. The
Fig. 1 Phylogenetic tree to show the relationship of factor H binding protein peptide types identified in invasive Neisseria meningitidis from
Québec, Canada, 2009-2013. *Peptide Id from the Neisseria.org website (http://pubmlst.org/neisseria/fHbp/). Factor H binding protein peptide
Id 1.1, 1.4, 1.12, 1.13, 1.14, 1.15, 1.100, 1.110, 1.129, 1.144, 1.218, 1.249, 1.278, 1.410, and 1.687 belong to Novartis variant 1 or subfamily B. Factor H
binding protein peptide Id 2.16, 2.19, 2.21, 2.22, 2.23, 2.24, 2.25, 2.102, 2.106, 2.527, 2.629, and 2.632 belong to Novartis variant 2 or subfamily A. Factor H
binding protein peptide Id 3.30, 3.47, and 3.555 belong to Novartis variant 3 or subfamily A. Dotted line indicates a negative branch length
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present study also identified ten STs within the Quebec
ST-269 CC but four of the STs found previously [30]
were not found in the present study, and three new STs
not previously found were included in here. Also of
interest is ST-275 and its SLV ST-1163 found in the
period of 2003-2010 did not appear to have expanded to
cause IMD in Québec. This was in contrast to the en-
demic MenB disease reported in England/Wales, where
the ST-275 clone has expanded while ST-269 clone has
decreased in frequency of detection among IMD case
isolates [27]. The difference between the molecular
epidemiology of MenB disease in Québec and England/
Wales might be in Québec MenB ST-269 has been as-
sociated with clusters of cases whereas in England/
Wales, the MenB disease has been characterized as en-
demic disease without any single clone dominating.
Our data may suggest that ST-269 strain in Québec
might have a unique advantage in establishing itself in
the population to cause significant disease over an ex-
tended period of time [30]. Indeed we speculated that
MenB strain of ST-269 has the potential to cause out-
breaks [31].
Among the MenB ST-41/44 CC isolates, ST-571 con-
tinued to be a common ST found, responsible for 37 %
of the MenB in this CC, similar to the finding reported
previously [30]. Isolates of ST-571 also appeared to have
a uniform antigenic formula expressing serotype antigen
19 (in all 16 isolates), and serosubtype antigen P1.9
(in 15 isolates) together with the PorA genotype of P1.18-
7, 9, 35-1 (in 15 isolates). Other MenB isolates within the
ST-41/44 CC or other CCs or those not belonging to any
known CC can essentially be described as diverse, not re-
stricted to any particular ST or antigenic form.
Analysis of the 4CMenB vaccine antigen genes among
the various meningococcal serogroups and CCs have
provided some interesting observations (Table 4). Al-
though MenB that belonged to the ST-269 CC might
not have any antigens that matched exactly with the
4CMenB vaccine components, a significant percentage
(96 % or 153 out of 159 isolates) were predicted to be
covered based on the majority of them possessed fHbp
genes that encoded for variant 1 fHbp peptide 1.15. The
coverage of this clone by the vaccine was further
supported by an in vitro assay Meningococcal Antigen
Typing System (MATS) that measures expression, and
cross-reactivity of the vaccine antigens on clinical iso-
lates. Using MATS, the majority of strains within the
ST-269 CC were covered by fHbp and NHBA; and the
coverage for strains typed as ST-269 was 95 % [32]. Also
all five MenB isolates of the ST-32 CC were also pre-
dicted to be covered by the vaccine, either because they
possessed genes that encoded for a matching 4CMenB
Fig. 2 Phylogenetic tree to show the relationship of Neisseria Heparin Binding Antigen peptide types in invasive Neisseria meningitidis from
Québec, Canada, 2009-2013. *Peptide Id from the Neisseria.org website (http://pubmlst.org/neisseria/NHBA). Variants were labelled with the
peptide Id. Dotted line indicates a negative branch length
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vaccine component (variant 1 fHbp peptide 1.1; two
isolates) or with genes that encoded for NadA variants
2/3 peptides (3 isolates). This finding is in line with
other observations that many MenB of ST-32 CC are
likely to be covered by the 4CMenB vaccine [19]. In con-
trast a small number of MenB isolates of the ST-41/44
CC (14 % or 6 out of 43 isolates) were predicted to be
covered, possibly because of the heterogeneity of strains
found in this CC. Of the 27 MenB that did not belong to
ST-269 and ST-41/44 CCs, only 12 or 44 % were pre-
dicted to be covered by the 4CMenB vaccine. Therefore,
aside from ST-269, ST-32 and ST-41/44 CCs, MenB of
other clonal types in Quebec might be only poorly cov-
ered by the vaccine according to the strains analysed in
this study. Besides MenB, 6 of the 7 ST-11 MenC were
predicted to be covered by the 4CMenB vaccine by
virtue of either their nadA genes encoding for variant
2/3 NadA peptides (3 isolates) or fHbp genes encoding
for variant 1 fHbp (3 isolates). In contrast, none of the
10 MenW and only 2 of the 16 MenY were predicted to
be covered by the vaccine (Table 4).
The number of MenB isolates in this study predicted
to synthesize variant 1 fHbp was greatly influenced by
the presence of a large number of the ST-269 CC iso-
lates which predominantly predicted to have fHbp pep-
tide 15 (variant 1). If this clone was removed from the
calculation, the number and percentage of MenB isolates
predicted to have variant 1, 2, 3 fHbp would be 23, 47,
and 5 isolates or 30.7, 62.7, and 6.7 %, respectively. The
percentage of MenB in Québec without the ST-269 CC
would be more comparable to the percentage of MenB
in Western Canada predicted to have variant 1 fHbp
(37.7 %) [33]. In Western Canada, the percentage of
MenB predicted to encode for variants 2 and 3 fHbp
were 34.8 % and 27.5 %, respectively The higher percent-
age of variant 3 fHbp found among MenB in Western
Canada (27.5 %) was due to the presence of the ST-
213 cc, which were predominantly (92 %) predicted to
have fHbp peptide 45 (variant 3) [33].
The number of MenC, Y, W, and X were relatively small
and therefore, prediction of how well the vaccine may or
may not work against these serogroups of meningococi in
Québec may change when more isolates are tested. The
34 MenC, Y, W, and X isolates were found to possess
diverse alleles of fHbp and nhba genes predicted to encode
for 13 different fHbp and eight NHBA peptide types.
However, only 4 (3 MenC and 1 MenY) isolates were pre-
dicted to have variant 1 fHbp while 28 isolates were pre-
dicted to have variant 2 fHbp; and 2 MenC were predicted
not to produce fHbp due to a frame-shift mutation in
their fHbp genes [28]. Among MenC, no two isolates were
found to have identical fHbp gene alleles; a phenomenon
linked to the ET-15 variant of MenC in the ST-11 CC
[34]. Also 4 of the 7 MenC isolates were found to have
their nadA genes disrupted by presence of IS1301 in the
coding region, thereby leading to no NadA protein pre-
dicted in these isolates [35]. NadA-2/3 peptides were pre-
dicted in 3 of the 34 non-B meningococci, including 2
MenC (NadA peptide 3) and one MenY (NadA peptide 8).
Despite conjugated MenC vaccination programs im-
plemented since 2001-2002 to cover all infants and ado-
lescents in the province, it appears invasive MenC
disease still occurred at a low level in the adult popula-
tion. Six of the seven MenC cases were in the age range
of 30 to 83 years (with a median age of 59.5 years); and
in one case the age information is not available. Also the
responsible MenC strain appears to be identical to the
hyper-virulent ET-15 clone prominent in prevalence be-
fore the MenC conjugate vaccine was implemented. The
continuing circulation of this MenC ET-15 clone with
the potential to cause outbreaks with severe outcome
[36], justifies the existence of an immunisation program
consisting of two MenC conjugate vaccine doses offered
at 12 months and 12 years of age, respectively [37], in
order to maintain the immunity in the population and to
keep the level of invasive MenC disease to a minimum
in the province. Genetic analysis of new MenB vaccine
targets suggested that the MenC ET-15 clone may be
covered by the fact that they all have nhba genes for
NHBA peptide 20 (which may cross-react with NHBA
peptide 2), or either presence of fHbp genes for variant 1
fHbp peptides in three isolates or nadA genes that
encoded for NadA peptide 2 or 3 in another three
isolates.
With the implementation of the Bexsero® vaccine in re-
gions of Quebec with the highest incidence of IMD due to
the ST-269 clone (authors’ unpublished data), attention
are now being focused on gathering data that would pro-
vide information on the efficacy of the vaccine, its safety
profile in the field, its acceptability by the population, its
effect on potential carriage and herd immunity, as well
as its potential effect on the circulating population of
N. menngitidis strains. This post-implementation surveil-
lance data would help to improve our knowledge of this
new vaccine and may assist in refining the dosage and/or
schedule of the vaccine, as well as its true strain coverage.
Conclusion
This study provided an overall molecular analysis of the
invasive N. meningitidis in Québec in recent years with
an intent to examine the genetic diversity and distribu-
tion of the newer meningococcal vaccine targets. For
MenB, eight strains were predicted to have one (six
isolates) or two (two isolates) antigens that matched
exactly with the respective component in the 4CMenB
vaccine. Six isolates (including two that also expressed
the PorA P1.4 antigen) were predicted to encode NHBA
peptide 2, and two isolates predicted to encode variant 1
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fHbp peptide 1.1. Another 165 MenB isolates might be
regarded to be covered by the vaccine by virtue of either
possessing genes for variant 1 fHbp or NadA variants 1,
2/3 peptides. For the 34 non-MenB isolates, only one
MenY was found to possess a nadA gene for the NadA
peptide 8 found in the 4CMenB vaccine. In addition
seven other isolates predicted to be potentially covered
by the vaccine by virtue of either possession of a fHbp
gene for variant 1 fHbp peptide (four isolates) or a nadA
gene for variant 2/3 NadA peptides (three isolates).
The major limitation is we did not perform assay to
examine expression of the newer vaccine targets in our
clinical isolates and their cross-reactivities with those
found in the vaccine. Also the number of isolates as a
whole were small which might affect the confidence
level of the finding. Furthermore, we did not have
clinical data on hand to compare the virulence of the
different genotypes identified, in particular those in the
ST-269 CC. Therefore, further prospective studies em-
ploying these tools and approaches may allow for a more
in-depth analysis of IMD in Québec, Canada.
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